rpl-12 Antibody

What is RPL12 and what is its primary function in cells?

RPL12 (also known as uL11) is a component of the 60S ribosomal subunit, specifically a component of the P stalk. It functions in the large ribonucleoprotein complex responsible for protein synthesis in cells. RPL12 binds directly to 26S ribosomal RNA and is located primarily in the cytoplasm. The ribosome's role as the cellular protein synthesis machinery makes RPL12 essential for translation processes . RPL12 has been found to influence translation rates, with its suppression leading to slower ribosome velocity that can affect protein folding and function .

What applications are RPL12 antibodies suitable for in research?

RPL12 antibodies are validated for multiple research applications including:

Most commercially available RPL12 antibodies are rabbit polyclonal antibodies and have been tested in multiple tissue types, including brain, stomach, placenta, and various cancer tissues . When designing experiments, it's important to select antibodies validated for your specific application and species of interest.

How do I determine the optimal RPL12 antibody for my specific experimental system?

When selecting an RPL12 antibody, consider these research-focused criteria:

• Epitope location: Some antibodies target the central region (amino acids 71-100) while others target N-terminal regions. Select based on your research question and protein accessibility in your experimental system .

• Validation data availability: Review the manufacturer's validation data. For example, Proteintech's antibody (14536-1-AP) includes Western blot data across various lysates and IHC images in multiple tissues and species .

• Species homology: RPL12 is highly conserved across species. Check sequence alignment for your model organism against the immunogen sequence to ensure epitope conservation .

• Application-specific performance: Some antibodies perform better in certain applications. For example, ab127533 shows strong performance in both WB and IHC-P applications in human and mouse samples .

What are the optimal protocols for using RPL12 antibodies in Western blot applications?

For Western blot applications with RPL12 antibodies, follow these research-validated protocols:

• Sample preparation: Use standard cell or tissue lysis procedures with protease inhibitors. RPL12 is abundantly expressed in most cell types.

• Gel selection: Use 12% SDS-PAGE for optimal separation as RPL12 has a predicted molecular weight of approximately 18 kDa but often runs at 21 kDa on gels .

• Transfer and blocking: Standard protocols apply; PVDF or nitrocellulose membranes are suitable.

• Antibody dilution: Start with 1:1000 dilution for most RPL12 antibodies in 5% BSA or milk-based blocking buffer .

• Detection: Both chemiluminescence and fluorescence-based detection systems work well with RPL12 antibodies.

• Expected results: Anticipate a band at approximately 18-21 kDa. Some variation in apparent molecular weight may occur due to post-translational modifications .

How should I optimize immunohistochemistry protocols for RPL12 detection in different tissue types?

For optimal IHC detection of RPL12 in paraffin-embedded tissues:

• Antigen retrieval: Heat-mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) provides superior results compared to citrate buffer for most RPL12 antibodies .

• Antibody concentration: Initial testing at 1:500 dilution is recommended for most tissues. Cancer tissues may require further optimization due to potential expression variations .

• Incubation conditions: Standard overnight incubation at 4°C often yields best results.

• Tissue-specific considerations:

  • For brain tissue: Extended antigen retrieval (20 minutes) may be necessary .

  • For gastrointestinal tissues: Background reduction techniques may be required due to high ribosomal content .

  • For cancer tissues: Compare with normal adjacent tissue as RPL12 expression may be altered .

• Controls: Include both positive controls (tissues known to express RPL12 such as placenta) and negative controls (primary antibody omission) .

What troubleshooting steps should I take when RPL12 antibody shows unexpected results?

When encountering unexpected results with RPL12 antibodies:

• Multiple/unexpected bands in Western blot:

  • Confirm sample integrity and protein degradation

  • Try reducing primary antibody concentration

  • Consider alternative antibodies targeting different epitopes

  • Remember that RPL12 has been observed at 21 kDa rather than its predicted 18 kDa in some systems

• Weak or absent signal in IHC:

  • Try extended antigen retrieval with Tris-EDTA buffer (pH 9.0)

  • Increase antibody concentration (up to 1:100)

  • Extend primary antibody incubation time

  • Consider amplification systems for low abundance detection

• High background in IHC:

  • Increase blocking duration and concentration

  • Reduce primary antibody concentration

  • Use more stringent washing conditions

  • Consider autofluorescence reduction techniques for fluorescent detection

How can RPL12 antibodies be used to study ribosome biogenesis and nuclear import pathways?

RPL12 has a distinct nuclear import pathway compared to other ribosomal proteins, making it valuable for studying specialized protein trafficking:

• Nuclear-cytoplasmic fractionation: Use RPL12 antibodies in combination with fractionation techniques to monitor RPL12 localization under different cellular conditions .

• Importin interaction studies: RPL12 specifically interacts with importin 11 rather than importin-β or importin 5 used by other ribosomal proteins. Co-immunoprecipitation with RPL12 antibodies can help elucidate these pathway-specific interactions .

• Transport assays: In vitro nuclear import assays using fluorescently labeled RPL12 and specific antibodies can reveal dynamics of this distinct pathway.

• Competition assays: RPL12 competes with UbcM2 for binding to importin 11, indicating these cargoes are not co-imported. This can be studied using pull-down assays with RPL12 antibodies .

The research data clearly shows that unlike other ribosomal proteins that use the general ribosomal protein import pathway (comprised of multiple karyopherins), RPL12 uses a distinct pathway mediated by importin 11 .

What insights can RPL12 antibodies provide in studies of translation regulation and protein folding?

RPL12 antibodies can be instrumental in investigating translation regulation mechanisms:

• Ribosome profiling complementation: RPL12 suppression affects both translation initiation and elongation rates. Antibodies can be used to confirm knockdown efficiency in such studies .

• Translation velocity effects: Research has shown that slowing ribosome velocity by RPL12 suppression can restore folding and function of mutant proteins like F508del-CFTR. RPL12 antibodies are essential for validating knockdown levels in these experiments .

• GC content sensitivity: Transcripts with high GC content show differential sensitivity to RPL12 levels. Antibodies can help establish the relationship between RPL12 abundance and translation of specific transcripts .

• Stress response mechanisms: RPL12 suppression doesn't activate integrated stress response pathways, suggesting specific effects on translation. RPL12 antibodies can help map these pathway interactions .

How can RPL12 antibodies be applied in cancer research?

RPL12 antibodies have specific applications in cancer research contexts:

• Expression profiling: Compare RPL12 expression levels between normal and cancer tissues using quantitative immunohistochemistry. Validation data shows distinct staining patterns in endometrial cancer and gastric carcinoma tissues .

• Ribosome heterogeneity: Investigate cancer-specific alterations in ribosome composition using RPL12 antibodies in conjunction with other ribosomal markers.

• Translation reprogramming: Cancer cells often exhibit altered translation programs. RPL12 antibodies can help characterize these changes in conjunction with polysome profiling.

• Therapeutic implications: Based on findings that modulation of RPL12 levels can affect protein folding, RPL12 targeting might represent a novel therapeutic approach for certain conditions. Antibodies are crucial for target validation studies .

How should I quantify and normalize RPL12 expression data in Western blot and IHC experiments?

For accurate quantification of RPL12 expression:

What controls should be included when studying RPL12 using RNA interference or gene editing techniques?

When manipulating RPL12 expression:

How do I interpret conflicting results between different RPL12 antibodies or detection techniques?

When facing discrepant results with RPL12 antibodies:

• Epitope considerations:

  • Compare the epitope regions of different antibodies

  • Some antibodies target the central region (aa 71-100) while others target different regions

  • Post-translational modifications may affect epitope accessibility

• Technique-specific factors:

  • Western blot: Denatured epitopes versus native conformation in other techniques

  • IHC: Fixation and antigen retrieval methods can dramatically affect results

  • IP techniques: Binding partners may mask certain epitopes

• Validation approaches:

  • Use genetic approaches (siRNA, CRISPR) to validate antibody specificity

  • Employ multiple antibodies targeting different epitopes

  • Consider mass spectrometry validation for absolute confirmation

  • Compare results across multiple cell lines or tissues

How is RPL12 involved in disease mechanisms beyond its role in general translation?

RPL12 has emerging roles in disease contexts that can be investigated using RPL12 antibodies:

• Protein folding diseases: RPL12 suppression can restore folding and function of mutant proteins like F508del-CFTR, relevant to cystic fibrosis. This suggests a broader role in protein quality control that may extend to other misfolding diseases .

• Translation-dependent diseases: Conditions involving altered translation rates or ribosome functions may involve RPL12. Antibodies can help characterize these mechanisms.

• Cancer progression: As a ribosomal protein with unique import properties, RPL12 may have cancer-specific functions beyond general translation that can be explored using specific antibodies in cancer models .

• Stress response pathways: Unlike general translation inhibition, RPL12 suppression does not activate integrated stress response pathways, suggesting specific regulatory roles that can be investigated with antibodies .

What are the most effective approaches for studying RPL12 interactions with other ribosomal and non-ribosomal proteins?

To study RPL12 protein interactions:

• Co-immunoprecipitation protocols:

  • Use antibodies recognizing different RPL12 epitopes to avoid disrupting specific interactions

  • Consider crosslinking approaches to capture transient interactions

  • Validate interactions using reciprocal co-IP

• Proximity labeling techniques:

  • BioID or APEX2 fusions with RPL12 can identify proximal proteins in living cells

  • Results should be validated using RPL12 antibodies in co-localization studies

• Structural biology approaches:

  • Cryo-EM studies of ribosomes can be complemented with RPL12 antibody labeling

  • Antibody epitope mapping can provide insights into functional domains

• Nuclear import pathway studies:

  • The specific interaction between RPL12 and importin 11 (versus importin-β or importin 5) presents a unique opportunity to study specialized nuclear import pathways

  • Competition assays between RPL12 and other importin 11 cargoes like UbcM2 can reveal regulatory mechanisms